# A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

> **NCT04283006** · EARLY_PHASE1 · RECRUITING · sponsor: **He Huang** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed and Refractory
- Lymphoid Hematological Malignancies

## Interventions

- **DRUG:** CD20/CD22 dual Targeted CAR T-cells

## Key facts

- **NCT ID:** NCT04283006
- **Lead sponsor:** He Huang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-05-23
- **Primary completion:** 2023-05-23
- **Final completion:** 2028-05-23
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283006, "A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04283006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*